Aion Therapeutic Inc. (ANTCF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $2.07M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAion Therapeutic Inc. (ANTCF) trades at $0.002. Aion Therapeutic Inc. focuses on developing medical cannabis products within Canada. The company rebranded from Osoyoos Cannabis Inc. in 2020 and maintains its headquarters in Toronto. Market cap: $2.07M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 1, 2026Analyst Coverage for ANTCF: ANTCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ANTCF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 19 months old (Jan 31, 2025), so the figures and score below describe that period, not today.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ANTCF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Aion Therapeutic Inc. (ANTCF) Healthcare & Pipeline Overview
Aion Therapeutic Inc. is a Canadian company focused on the medical cannabis sector, offering specialized products within a competitive market. Operating with a negative profit margin and trading on the OTC market, Aion faces challenges in a rapidly evolving industry landscape.
What Is the Investment Thesis for ANTCF?
Investing in Aion Therapeutic Inc. presents significant risks due to its OTC listing and negative profit margin of -1710.9%. The company's gross margin stands at 44.4%. Aion's success hinges on its ability to innovate within the medical cannabis space and effectively market its products in Canada. Potential catalysts include regulatory changes favoring medical cannabis and successful product launches. However, investors should be wary of the risks associated with OTC-listed companies, including limited liquidity and disclosure. The company's beta of -0.55 suggests a negative correlation with the market, but this may not hold true given its small size and specific industry focus. The absence of a dividend further reduces the attractiveness for income-seeking investors.
Based on FMP financials and quantitative analysis
ANTCF Key Highlights
Market Cap: $2.07M indicates a micro-cap company with limited resources and higher volatility.
- Profit Margin: -1710.9% signals significant losses and potential financial instability.
- Gross Margin: 44.4% suggests the company can generate revenue above the direct cost of goods, but operating expenses are a major concern.
- Beta: -0.55 indicates a negative correlation with the market, but may not be reliable due to the company's size and OTC status.
- Dividend Yield: None reflects the company's current inability to return capital to shareholders.
Who Are ANTCF's Competitors?
ANTCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BGM BGM Group Ltd. | $0.28 | +0.92% | $105M | 455-pillar |
| MEDXF Medexus Pharmaceuticals Inc. | $3.59 | -1.40% | $114M | 479-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are ANTCF's Key Strengths?
Focus on medical cannabis applications.
- Established presence in the Canadian market.
- Potential for product innovation.
- Proprietary cannabis formulations.
What Are ANTCF's Weaknesses?
Negative profit margin.
- Limited market capitalization.
- OTC listing indicates higher risk.
- Dependence on the Canadian market.
What Could Drive ANTCF Stock Higher?
Regulatory changes in Canada favoring medical cannabis.
- Successful launch of new cannabis-based products.
- Increasing acceptance of medical cannabis among healthcare professionals.
- Expansion of distribution networks within Canada.
What Are the Key Risks for ANTCF?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger cannabis companies.
- Fluctuations in cannabis prices.
- Product recalls or safety concerns.
- Negative profit margin and financial instability.
- OTC listing indicates higher risk and limited liquidity.
What Are the Growth Opportunities for ANTCF?
- Expansion into New Therapeutic Areas: Aion could explore developing cannabis-based treatments for specific medical conditions, such as chronic pain, anxiety, or sleep disorders. The market for cannabis-based pharmaceuticals is growing as research validates its therapeutic potential. Success would depend on clinical trials and regulatory approvals, with a timeline of 3-5 years to commercialization. This could significantly increase their market share within the medical cannabis sector.
- Strategic Partnerships: Collaborating with established pharmaceutical companies or healthcare providers could provide Aion with access to wider distribution networks and expertise in drug development. These partnerships could accelerate product development and market penetration. The timeline for establishing such partnerships is approximately 1-2 years, and the impact could be substantial in terms of market reach and credibility.
- Product Innovation: Developing novel cannabis formulations or delivery methods could differentiate Aion from its competitors. This could include developing new strains with specific cannabinoid profiles or creating innovative products like transdermal patches or inhalers. The timeline for product innovation is approximately 2-3 years, and success would depend on regulatory approval and consumer acceptance.
- Geographic Expansion within Canada: Expanding its distribution network to new provinces and territories within Canada could increase Aion's market reach. This would involve navigating different regulatory frameworks and establishing relationships with local retailers and healthcare providers. The timeline for geographic expansion is approximately 1-2 years, and the impact would depend on the size and potential of the new markets.
- Focus on Medical Cannabis Education: Investing in educational initiatives to inform healthcare professionals and patients about the benefits of medical cannabis could drive demand for Aion's products. This could involve conducting webinars, publishing research, and partnering with medical organizations. The timeline for seeing results from educational initiatives is approximately 2-3 years, and the impact would depend on the reach and effectiveness of the programs.
What Are ANTCF's Competitive Advantages?
- Proprietary cannabis formulations.
- Established relationships with healthcare providers.
- Brand recognition within the Canadian medical cannabis market.
- Intellectual property protection for novel cannabis products.
What Does ANTCF Do?
Aion Therapeutic Inc., formerly known as Osoyoos Cannabis Inc., was incorporated in 2011 and rebranded in August 2020 to reflect its focus on therapeutic applications of cannabis. Headquartered in Toronto, Canada, the company is involved in the development and distribution of medical cannabis products. Aion's products are tailored for the Canadian market, where regulations and consumer demand are evolving. The company aims to leverage cannabis's therapeutic potential, though specific product details and market strategies are not extensively detailed in available information. Aion operates within the broader context of the Canadian cannabis industry, which has seen significant growth and regulatory changes since the legalization of recreational cannabis in 2018. The company's success depends on navigating regulatory hurdles, developing effective products, and establishing a strong market presence. Aion's relatively small market capitalization suggests it is a minor player compared to larger, more established companies in the cannabis sector.
What Products and Services Does ANTCF Offer?
- Develop medical cannabis products.
- Offer cannabis-based therapies for various conditions.
- Engage in research and development of cannabis formulations.
- Distribute medical cannabis products within Canada.
- Focus on therapeutic applications of cannabis.
- Navigate the regulatory landscape of the Canadian cannabis industry.
How Does ANTCF Make Money?
- Develop and market medical cannabis products.
- Generate revenue through product sales.
- Focus on the Canadian medical cannabis market.
- Potentially license intellectual property related to cannabis formulations.
What Industry Does ANTCF Operate In?
Aion Therapeutic Inc. operates in the rapidly evolving Canadian cannabis industry, which has seen significant growth since legalization. The market is characterized by increasing competition and regulatory changes. Companies like Aion face the challenge of differentiating themselves through product innovation and effective marketing. The industry is also subject to evolving consumer preferences and regulatory scrutiny. Aion's ability to navigate these challenges and capitalize on the growing demand for medical cannabis will determine its long-term success. The Canadian cannabis market is projected to continue growing, driven by increasing acceptance and expanding applications of cannabis products.
Who Are ANTCF's Key Customers?
- Patients seeking medical cannabis treatments.
- Healthcare providers recommending cannabis therapies.
- Pharmacies and dispensaries distributing cannabis products.
- Research institutions studying cannabis applications.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 588 days ago
- ● No analyst coverage
- ● Reported in CAD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 50 |
| 2026-08-26 | 50 |
| 2026-08-29 | 50 |
| 2026-09-01 | 50 |
| 2026-09-04 | 50 |
| 2026-09-07 | 50 |
| 2026-09-10 | 50 |
What changed?
The score has stayed at 50.
Over the same 18 days the stock moved +0.0%.
Financial Health
Aion Therapeutic Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Aion Therapeutic Inc. stands at 190.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -34.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
Aion Therapeutic Inc. (ANTCF) Valuation Context
Valued at $2.07M, ANTCF is classified as a micro-cap stock.
ANTCF Revenue & Earnings Trend
In Q3 FY2025, ANTCF generated $393K in top-line revenue, marking a sequential increase of 56.8%. The company recorded a net loss of $211K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ANTCF averaged $-0.00 in diluted EPS.
Company Profile
Aion Therapeutic Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO John Graham Simmonds Jr.. ANTCF has traded publicly since 2021.
ANTCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on medical cannabis applications.
- Established presence in the Canadian market.
- Potential for product innovation.
- Proprietary cannabis formulations.
Bear Case
- Negative profit margin.
- Limited market capitalization.
- OTC listing indicates higher risk.
- Dependence on the Canadian market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2025 | $392,977.784 | -$210,889.941 | -$0.0004 |
| Q2 FY2025 | $250,665.435 | -$420,254.798 | -$0.0009 |
| Q1 FY2025 | $313,568.849 | -$267,384.396 | -$0.0007 |
| Q4 FY2024 | $104,870.991 | -$4M | -$0.01 |
Q3 FY2025 · filed 31 Jan 2025 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CAD at today's rate
ANTCF Latest News
No recent news available for ANTCF.
ANTCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ANTCF.
Price Targets
Wall Street price target analysis for ANTCF.
ANTCF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ANTCF; grades run from A+ (80-100) to F (below 30).
Leadership: John Graham Simmonds Jr.
CEO
Without further information, it is impossible to provide details on his career history, education, or previous roles.
Track Record: Due to the lack of information on John Graham Simmonds Jr.'s background, it is impossible to assess his track record or provide details on key achievements, strategic decisions, or company milestones under his leadership. His contributions to Aion Therapeutic Inc. cannot be evaluated based on the provided data.
ANTCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aion Therapeutic Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in OTC Other companies carries significant risks due to the potential for fraud, manipulation, and lack of transparency. These companies are not required to adhere to the same stringent reporting standards as those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of transparency due to minimal disclosure requirements.
- Potential for fraud or manipulation.
- Higher volatility compared to exchange-listed stocks.
- Shell Risk Detected indicates a high risk of the company being a shell corporation.
- Verify the company's registration and legal status.
- Investigate the background and experience of the management team.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's cash flow and financial stability.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor before investing.
- Company has been incorporated since 2011.
- Focus on the medical cannabis sector.
- Operates in the regulated Canadian market.
- Gross Margin above 0%.
Common Questions About ANTCF (Healthcare)
Is ANTCF a good stock?
Stock Expert AI does not rate ANTCF buy, sell or hold. Aion Therapeutic Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about ANTCF stock?
There is no available analyst coverage for ANTCF stock due to its OTC listing and small market capitalization. Therefore, no analyst consensus, valuation metrics, or growth considerations are available.
What are the key factors to evaluate for ANTCF?
Evaluate ANTCF on fundamentals, analyst consensus, and risk factors. Investing in Aion Therapeutic Inc. presents significant risks due to its OTC listing and negative profit margin of -1710.9%. Not financial advice.
How frequently does ANTCF data refresh on this page?
ANTCF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ANTCF's recent stock price performance?
Aion Therapeutic Inc. (ANTCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on medical cannabis applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ANTCF overvalued or undervalued right now?
Aion Therapeutic Inc. (ANTCF) is loss-making, so its trailing P/E is negative (-1.99x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ANTCF?
Yes, most major brokerages offer fractional shares of Aion Therapeutic Inc. (ANTCF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ANTCF's earnings and financial reports?
Aion Therapeutic Inc. (ANTCF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ANTCF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Aion Therapeutic Inc.
- OTC stocks are inherently riskier than exchange-listed stocks.
- Financial data may not be up-to-date or reliable.